Repair Biotechnologies is dedicated to developing innovative treatments to address excess cholesterol buildup causing atherosclerosis. In the context of anti-aging therapies this is incredibly interesting as one in three people around the world die from cardiovascular disease, which is mainly caused by atherosclerosis. With a focus on counteracting this buildup with their innovative Cholesterol Degrading Platform (CDP), the company seeks to extend healthy human lifespans.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
Central to Repair Biotechnologies’ efforts is the Cholesterol Degrading Platform (CDP). This platform is designed to reduce harmful cholesterol deposits across various organs, including the heart and liver. In preclinical studies, the CDP has demonstrated significant potential in reversing atherosclerosis, a common cardiovascular condition and leading cause of death. The modular nature of the CDP allows it to be tailored to different medical needs, making it a versatile tool in the fight against age-related conditions.
The CDP focuses on breaking down and removing harmful cholesterol deposits from the body. It employs engineered enzymes capable of degrading cholesterol in tissues, effectively reducing the risk and impact of related diseases. This approach targets the underlying problem rather than just managing symptoms, promising a more effective and long-term solution.
In the following you will find the official pipeline:
As the pipeline shows the company is at the cusp of human clinical trials for applying CDP to reducing cholesterol buildup. Their goal is to move from successful preclinical models to human trials, ensuring that the technology can be safely and effectively used in medical practice.
There are many potential benefits if the CDP solution is indeed a scientific breakthrough. The following sums up the possible applications of CDP:
- Atherosclerosis: In preclinical trials, the CDP has shown impressive results in reversing atherosclerosis in mouse models. By clearing cholesterol buildup in arteries, it helps restore normal blood flow and reduces the risk of heart attacks and strokes.
- Cardiovascular Health: Beyond atherosclerosis, the CDP has the potential to improve overall cardiovascular health. By maintaining lower cholesterol levels, it can prevent the progression of various heart diseases.
- Organ Health: The modular nature of CDP allows it to be adapted for different organs, including the liver, lungs, and brain. Each application targets cholesterol deposits specific to that organ, enhancing overall functionality and health.
- Chronic Conditions: By addressing cholesterol buildup, CDP may also mitigate the effects of chronic conditions linked to aging, such as chronic obstructive pulmonary disease (COPD) and certain neurodegenerative diseases.
The Company
Repair Biotechnologies was founded in 2018 in Syracuse, New York, by a person simply referred to as Reason, a well-known advocate for longevity science, and Bill Cherman, an experienced entrepreneur in the biotech sector.
In May of 2025 the FDA granted Repair Biotechnologies an Orphan Drug Designation to its drug REP-0003 for the treatment of patients with familial hypercholesterolemia, and as such accelerating the clinical trials for their lead candidate.
While funding has been secured, with the most recent funding being raised in June 2023, there is scarce information as to the amounts of funding the company has received. As such it is difficult to assess the current capabilities of the company to carry out their pipeline ambitions, and next step clinical trials.
Read about more anti-aging companies on this website through this link.
